Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1. Maintaining and improving quality of care within HIV clinical services

Maintaining and improving quality of care within HIV clinical services MAINTAINING AND IMPROVING QUALITY OF CARE WITHIN HIV CLINICAL SERVICES JULY 2019 TECHNICAL BRIEF HIV TREATMENT WHO/CDS/HIV/19.17 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute (...) : “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Maintaining and improving quality of care within HIV clinical services. Geneva, Switzerland: World Health

2019 World Health Organisation HIV Guidelines

2. Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents

Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents Prescrire IN ENGLISH - Spotlight ''Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents'', 1 July 2019 {1} {1} {1} | | > > > Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents FREE DOWNLOAD Based on extrapolation of the data obtained in adults, the emtricitabine + tenofovir disoproxil combination (Truvada° or other brands) appears worth offering to adolescents whose sex practices place them at particularly

2019 Prescrire

3. Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services

Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services , , , , Questions (...) What strategies have been successful at linking people with undiagnosed HIV infection to HIV testing, care, and prevention services? Key take-home messages A variety of strategies have shown promise for identifying individuals with undiagnosed HIV and engaging them with HIV testing using clinical, community-based, network-based, and self-directed approaches. Various service delivery models for implementing rapid initiation of antiretroviral treatment have demonstrated benefits for linking the newly

2019 Ontario HIV Treatment Network

4. Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection

Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Document ID CHQ-GDL-01243 Version no. 3.1 Approval date 28/05/2019 Executive sponsor Executive Director Medical Services Effective date 28/05/2019 Author/custodian Infectious Diseases Physician - Infection Management and Prevention services Review date 28/05/2021 Supercedes 3.0 Applicable to All Children’s Health Queensland (...) staff Authorisation Executive Director Clinical Services (QCH) Purpose This guideline provides best practice recommendations for obstetricians, paediatricians, neonatologists and Human Immunodeficient Virus (HIV) physicians regarding management of infants born to women with HIV infection. Scope This Guideline provides information for all Children’s Health Queensland (CHQ) employees (permanent, temporary and casual) and all organisations and individuals acting as its agents (including Visiting

2019 Queensland Health

5. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3.To update (...) the 2012 review on HIV screening to inform the USPSTF.Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019.Nonpregnant individuals 12 years and older; randomized clinical trials (RCTs) and controlled observational studies of screening vs no screening, alternative screening strategies, earlier vs later initiation of ART, and long-term harms of ART.One investigator abstracted data

2019 JAMA

6. Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Prenatal screening for HIV can inform use of interventions to reduce the risk of mother-to-child transmission. The US Preventive Services Task Force (USPSTF) previously found strong evidence that prenatal HIV screening reduced risk of mother-to-child transmission. The previous evidence review was conducted in 2012.To update the 2012 review on prenatal HIV (...) groups.One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.Mother-to-child transmission; harms of screening and treatment; screening yield.Sixty-two studies were included in this review, including 29 new studies. There remains no direct evidence on effects of prenatal screening vs no screening on risk of mother-to-child HIV transmission, maternal or infant clinical outcomes, or the yield of repeat or alternative screening strategies. New

2019 JAMA

7. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Final Update Summary: Human Immunodeficiency Virus (HIV) Infection: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Human Immunodeficiency Virus (HIV) Infection: Screening Release Date: June 2019 Recommendation Summary Population Recommendation (...) Grade Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. To read the recommendation statement in JAMA , select

2019 U.S. Preventive Services Task Force

8. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis Final Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure (...) Prophylaxis Release Date: June 2019 Recommendation Summary Population Recommendation Grade Persons at high risk of HIV acquisition The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . See the for information about identification of persons at high risk and selection of effective antiretroviral

2019 U.S. Preventive Services Task Force

9. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV 14 June 2019 Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health Information and Quality Authority Page 2 of 257 Health technology assessment of a PrEP programme for populations at substantial risk (...) of sexual acquisition of HIV Health Information and Quality Authority Page 3 of 257 CONTENTS About the Health Information and Quality Authority (HIQA) 6 Foreword 7 Acknowledgements 8 Advice to the Minister for Health 10 Executive summary 15 Plain English summary 26 1 Introduction 28 1.1 Background to the request 28 1.2 Terms of reference 29 1.3 Overall approach 29 2 Description of technology 31 2.1 Background 32 2.2 Regulatory status of PrEP 33 2.3 Product information 33 2.4 PrEP use in Ireland 35 2.5

2019 Health Information and Quality Authority

10. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. (PubMed)

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual (...) couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2

Full Text available with Trip Pro

2019 Lancet

11. Out-of-pocket costs associated with HIV in publicly funded high-income health care settings

Out-of-pocket costs associated with HIV in publicly funded high-income health care settings Out-of-pocket costs associated with HIV in publicly funded high-income health care settings | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Out-of-pocket costs associated with HIV in publicly funded high-income health care settings Out-of-pocket costs associated with HIV in publicly funded high-income health care settings , , Question What out-of-pocket costs are associated (...) with aging among people living with HIV? Key take-home messages The aging of the people living with HIV in care is leading to increased HIV care costs (1). There is considerable inter-jurisdictional heterogeneity in the cost-sharing policies for antiretrovirals across Canada’s public drug programs (2). Out-of-pocket costs such as inadequate drug coverage, pharmacy dispensing fees, and clinic travel costs may affect treatment adherence and related health outcomes among people living with HIV (3, 4

2019 Ontario HIV Treatment Network

12. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection | The Ontario HIV Treatment Network The Ontario HIV Treatment Network A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

13. Monitoring Progress of Neurological and Functional Outcomes in the Paediatric HIV Cohort in the UK

Monitoring Progress of Neurological and Functional Outcomes in the Paediatric HIV Cohort in the UK Developmental Monitoring Guidelines 2019 1 Monitoring Progress of Neurological and Functional Outcomes in the Paediatric HIV Cohort in the UK Authors: Anita Freeman, Clinical Psychologist, Paediatric Department, St Mary’s Hospital Jackie Nicholson, Clinical Psychologist, Paediatric Psychosocial Service, Manchester Children’s Hospital Philippa Hatton, Clinical psychologist, Great Ormond Street (...) referral 10 CONCLUSIONS 11 References 12 2 Summary This document aims to summarise the current understanding of neurological and functional outcomes for children living with HIV and provide recommendations for screening and monitoring, as well as the process for deciding when to refer for or carry out additional assessments. This guideline gives a summary of some of the literature relating to the neurological and functioning outcomes of children and young people living with HIV. It is aimed

2019 The Children's HIV Association

14. BHIVA guidelines on the management of HIV in pregnancy and postpartum

BHIVA guidelines on the management of HIV in pregnancy and postpartum British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 BHIVA guidelines on the management of HIV in pregnancy and postpartum 2 Guideline writing group Dr Yvonne Gilleece (Chair) Honorary Clinical Senior Lecturer and Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust Dr Shema Tariq (Vice-chair) Postdoctoral Clinical Research Fellow (...) , University College London, and Honorary Consultant Physician in HIV, Central and North West London NHS Foundation Trust Dr Alasdair Bamford Consultant in Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London Dr Sanjay Bhagani Consultant Physician in Infectious Diseases, Royal Free Hospital NHS Trust, London Dr Laura Byrne Locum Consultant in HIV Medicine, St George’s University Hospitals NHS Foundation Trust, London Dr Emily Clarke Consultant

2019 British HIV Association

15. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. (PubMed)

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. Administration of a single broadly neutralizing human immunodeficiency virus (HIV)-specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance (...) in HIV-infected persons after analytic treatment interruption.We conducted a nonrandomized, open-label, phase 2 clinical study evaluating the safety, pharmacokinetics, and antiviral activity of UB-421 monotherapy in HIV-infected persons undergoing analytic treatment interruption. All the participants had undetectable plasma viremia (<20 copies of HIV RNA per milliliter) at the screening visit. After discontinuation of ART, participants received eight intravenous infusions of UB-421, at a dose

2019 NEJM

16. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. (PubMed)

Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following (...) PrEP commencement.The Pre-exposure Prophylaxis Expanded (PrEPX) Study, a multisite, open-label intervention study, was nested within the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) clinic network. A total of 4275 participants were enrolled (July 26, 2016-April 1, 2018) in Victoria, Australia. Of these, 2981 enrolled at 5 ACCESS clinics (3 primary care, 1 sexual health, and 1 community-based HIV rapid testing service), had at least 1 follow-up visit, and were

2019 JAMA

17. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. (PubMed)

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Dolutegravir is superior to efavirenz for HIV antiretroviral therapy (ART) but may be associated with an increased risk for neural tube defects (NTDs) in newborns if used by women at conception.To project clinical outcomes of ART policies for women of child-bearing potential in South Africa.Model of 3 strategies: efavirenz for all women of child (...) -bearing potential (EFV), dolutegravir for all women of child-bearing potential (DTG), or World Health Organization (WHO)-recommended efavirenz without contraception or dolutegravir with contraception (WHO approach).Published data on NTD risks (efavirenz, 0.05%; dolutegravir, 0.67% [Tsepamo study]), 48-week ART efficacy with initiation (efavirenz, 60% to 91%; dolutegravir, 96%), and age-stratified fertility rates (2 to 139 per 1000 women).3.1 million South African women with HIV (aged 15 to 49 years

2019 Annals of Internal Medicine

18. The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities

The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities , , Questions What (...) is the impact of geographical location on implementation of HIV/STI prevention programs or interventions among LGBTQ communities? Key take-home messages The characteristics of a location, including segregation, community-level stigma, and infrastructural resources, may influence HIV service utilization and the HIV continuum of care among men who have sex with men (1). Implementation of HIV prevention interventions may be affected by whether a location is convenient, allows for anonymity, and makes one

2019 Ontario HIV Treatment Network

19. The efficacy of post-exposure prophylaxis (PEP) for HIV

The efficacy of post-exposure prophylaxis (PEP) for HIV The efficacy of post-exposure prophylaxis (PEP) for HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The efficacy of post-exposure prophylaxis (PEP) for HIV The efficacy of post-exposure prophylaxis (PEP) for HIV , , , Questions What is the efficacy of PEP when used for non-occupational exposure? What is the efficacy of PEP when used for occupational exposure? Are specific PEP regimens more efficacious than others (...) ? What are key factors implicated in the efficacy or inefficacy of PEP? Key take-home messages PEP initiated soon after exposure can reduce the risk of HIV seroconversion after occupational and non-occupational exposures, provided adherence to medications is sufficient (1–4). Evidence suggests that individuals prescribed tenofovir-based two- or three-drug regimens are more likely to complete a course of PEP and have lower discontinuation rates due to adverse events compared to zidovudine-based

2019 Ontario HIV Treatment Network

20. Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1)

Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register